How Does Vagifem Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Vagifem Works
- Active Ingredient: Estradiol hemihydrate (10 µg estradiol per tablet) – identical to the oestrogen produced by the ovaries.
- Local Action: Replaces declining oestrogen directly in vaginal tissues, reversing atrophy, restoring pH, and improving lubrication.
- Minimal Systemic Absorption: Plasma estradiol levels remain within normal postmenopausal range, avoiding systemic HRT risks for most women.
- Onset & Duration: Symptom improvement typically seen within 2–4 weeks; maintenance twice‑weekly dosing sustains effect.
- Safety Profile: No increased risk of breast cancer or venous thromboembolism with local vaginal oestrogen; avoids endometrial stimulation.
Vagifem delivers a low dose of oestrogen directly to the vaginal mucosa, restoring the natural physiology of the vaginal wall without significant systemic exposure. This targeted approach effectively treats postmenopausal vaginal atrophy (dryness, irritation, dyspareunia) while minimising the risks associated with systemic hormone replacement therapy.
Important Medical Advice
Stop using Vagifem and seek immediate medical attention if you develop: migraine‑like headaches, yellowing of skin/eyes (jaundice), swollen face/tongue/throat (signs of angioedema), sudden chest pain or difficulty breathing (possible blood clot), or any signs of a new blood clot (painful leg swelling, unexplained breathlessness). Also stop if you become pregnant or suspect pregnancy.
Chemical Composition & Molecular Structure
Vagifem vaginal tablets contain the active substance estradiol (as estradiol hemihydrate) at a dose of 10 micrograms per tablet. Estradiol is the most potent and predominant oestrogen in premenopausal women, chemically identical to the hormone produced by the ovaries.
Structural Details
estra‑1,3,5(10)‑triene‑3,17β‑diol
A steroid hormone with a phenolic A‑ring and a hydroxyl group at C‑17β. The hemihydrate form improves stability and dissolution characteristics.
Excipients & Formulation
| Excipient | Function |
|---|---|
| Hypromellose | Matrix former; controls tablet dissolution and mucosal adhesion |
| Lactose monohydrate | Bulking agent and carrier |
| Maize starch | Disintegrant; aids rapid tablet breakup in vaginal moisture |
| Magnesium stearate | Lubricant for tablet compression |
| Macrogol 6000 | Film‑coating component; enhances smoothness |
🗒️ Pharmaceutical insight: The low‑dose tablet is designed for rapid hydration and adhesion to the vaginal wall. Each tablet is supplied in a single‑use applicator, ensuring hygienic and accurate placement.
Mechanism of Action: Local Oestrogen Therapy
After insertion, the Vagifem tablet dissolves in the vaginal fluid. Estradiol diffuses into the epithelial cells and binds to oestrogen receptors (ERα and ERβ) located in the nuclei of vaginal, urethral, and trigone cells. The receptor‑hormone complex interacts with oestrogen response elements on DNA, triggering genomic effects that reverse atrophic changes.
- Re‑epithelialisation: Increased cell proliferation and maturation restore a thick, glycogen‑rich superficial layer.
- pH normalisation: Lactobacilli utilise glycogen to produce lactic acid, lowering vaginal pH from >5.5 to ≤4.5–5.0, which suppresses pathogenic bacteria.
- Increased blood flow & lubrication: Neovascularisation and improved blood supply enhance transudate production and elasticity.
- Urogenital tissue support: Strengthens the urethral and bladder neck mucosa, reducing urinary frequency and urgency (often associated with atrophy).
| Parameter | Before Vagifem | After 12 Weeks Treatment |
|---|---|---|
| Vaginal pH | 5.5–7.0 | 4.5–5.0 |
| Superficial cell percentage | <10% | ≥50% |
| Maturation index (parabasal/intermediate/superficial) | High parabasal | Predominantly superficial |
🗒️ Physiological insight: Unlike systemic HRT, the ultra‑low dose (10 µg) is insufficient to stimulate the endometrium or produce sustained systemic effects, making it suitable for women who cannot take oral oestrogen.
Pharmacokinetics: Absorption & Distribution
Vaginal administration bypasses first‑pass hepatic metabolism. After dissolution, estradiol is rapidly absorbed through the well‑vascularised vaginal mucosa. Peak plasma concentrations occur within 1–2 hours, but levels remain in the postmenopausal range (<20 pg/mL). The mean systemic bioavailability of intravaginal estradiol is approximately 10‑fold lower than that of oral oestrogen.
Local vs Systemic Exposure
Studies using 10 µg estradiol daily for 2 weeks followed by twice‑weekly maintenance show serum estradiol concentrations averaging 6.9 pg/mL (range 2–15 pg/mL) – well within normal postmenopausal values (typically <20 pg/mL).
Tissue Selectivity
Due to the low dose and local delivery, estradiol concentrations in the vaginal mucosa are several hundred‑fold higher than in plasma, ensuring efficacy with minimal systemic exposure.
Metabolic Effects & Elimination
Estradiol is metabolised primarily in the liver via oxidation to estrone and estrone sulfate, which have weak oestrogenic activity. Further conjugation (glucuronidation, sulfation) produces water‑soluble metabolites excreted in urine and faeces. With vaginal administration, first‑pass hepatic metabolism is avoided, but any small amount that reaches the circulation undergoes rapid conversion. The elimination half‑life of estradiol is approximately 1–2 hours.
⚠️ Metabolic caution: Although systemic exposure is minimal, women with severe hepatic impairment should use Vagifem with caution. Concurrent use of potent CYP3A4 inducers (e.g., rifampicin, carbamazepine) may theoretically reduce estradiol activity, though no significant interactions have been reported with the vaginal route.
Clinical Efficacy in Vaginal Atrophy
In randomised controlled trials, Vagifem 10 µg administered daily for 2 weeks then twice weekly for 12 weeks produced significant improvements:
- Reduction in vaginal dryness, soreness, and dyspareunia (painful intercourse) by ≥70%
- Normalisation of vaginal pH in 85% of users
- Increase in superficial cells from a baseline of 5% to >50%
- Subjective improvement in sexual function and quality of life
The SMART (Symbicort Maintenance and Reliever Therapy) equivalent is not applicable, but the twice‑weekly maintenance regimen is convenient and well‑tolerated. Long‑term use (≥1 year) is considered safe for most women, with annual check‑ups recommended to reassess need.
Vagifem FAQs
How long does it take for Vagifem to start working?
Many women notice relief from vaginal dryness and irritation within 2–4 weeks of starting treatment. Full improvement in tissue health and comfort typically occurs after 8–12 weeks of regular use.
Is Vagifem absorbed into the bloodstream?
Yes, but absorption is minimal. The 10 µg dose keeps serum estradiol levels within normal postmenopausal ranges (<20 pg/mL), so it does not produce systemic effects like breast tenderness or endometrial thickening.
Can I use Vagifem if I have a history of breast cancer?
Vagifem is contraindicated in women with current or past breast cancer. The safety in breast cancer survivors has not been established; your doctor will consider non‑hormonal alternatives.
What happens if I miss a dose?
If you forget a dose during the initial 2‑week daily phase, insert it as soon as you remember. Do not double the dose. For maintenance (twice weekly), skip the missed dose and continue with the next scheduled dose.
Does Vagifem affect the womb lining?
No. The low dose and local delivery mean that estradiol does not reach the endometrium in sufficient amounts to cause hyperplasia. No progestogen is needed when used as directed.
Need Vagifem with Expert Guidance?
If you are experiencing symptoms of vaginal atrophy, a UK‑registered doctor can assess your suitability for Vagifem and provide a prescription after an online consultation.
Secure Prescription & Next‑Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Menopause ConsultationRelated Vagifem Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 28 March 2026
Next Review: 28 September 2026
Published on: 28 March 2026
Last Updated: 28 March 2026